OMICS International Organises 3000+ Global Conferenceseries Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
For more Conferences visit


Alan Prem Kumar

Alan Prem Kumar

National University of Singapore



Alan Prem Kumar earned his Ph.D. from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas. Dr. Kumar then pursued Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors. Dr. Kumar relocated back to Singapore to join Cancer Science Institute of Singapore, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer pharmacology. His current research interest includes the role of nuclear receptors involved in the regulation of target genes and to elucidate mechanism and associated signal pathways. Another area of interest is aimed at developing new derivative drugs with hopefully fewer side effects. Over the years, Dr. Kumar and his laboratory have forged relationships with scientists in cancer research and with cancer advocacy groups in Singapore.


My primary research focuses in the areas of signaling by nuclear receptors and oncogenes as well as the development of molecular therapeutics and biomarkers of drug action in human breast cancer. We recently identified a novel oncogene that regulates a key pathway controlling cell proliferation, migration and drug resistance in breast, prostate, gastric, and colon cancers. Current research also focuses on developing therapeutic strategies to target this marker with the ultimate aim of conducting translational studies in patients.